Article
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2020
Hofman Véronique, Benzaquen Jonathan, Heeke Simon, Lassalle Sandra, Poudenx Michel, Long Elodie, Lantéri Elisabeth, Bordone Olivier, Lespinet Virginie, Tanga Virginie, Bonnetaud Christelle, Bille Yvonne, Ilié Marius, Marquette Charles, Barlesi Fabrice, Boutros Jacques, Hofman Paul
Abstract excerpt
INTRODUCTION: International guidelines recommend BRAF mutational status assessment in treatment-naive advanced non-squamous non-small cell lung carcinoma (NSCLC) patients since the presence of a BRAFV600 mutation enables specific BRAF inhibitor treatment. For this purpose, the mutational status n...
Topics
- Carcinoma
- France
- Humans
- Immunohistochemistry
- Laboratories
- Lung
- Lung Neoplasms
- Mutation
- Prospective Studies
- Proto-Oncogene Proteins B-raf
- Retrospective Studies
